HIV-associated lymphoma: promising new results, but with toxicity.
Treatment of HIV-associated non-Hodgkin lymphoma with rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide resulted in high complete remission and 2-year failure free and overall survival rates but a high rate of infection.
Straus
David J
DJ
Memorial Sloan-Kettering Cancer Center.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use* / Q000633:toxicity; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D007239:Infections / Q000139:chemically induced; D016483:Lymphoma, AIDS-Related / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide